Molecular biologists have elucidated general principles about chromosomal translocations by cloning oncogenes or fusion genes at chromosomal translocation junctions. These genes invariably encode intracellular proteins and in acute cancers, often involve transcription and developmental regulators, which are master regulators of cell fate (e.g. LMO2 which is involved in acute leukaemia). Chromosomal translocations are usually associated with speci®c cell types. The reason for this close association is under investigation using mouse models. We are trying to emulate the cell-speci®c consequences of chromosomal translocations in mice using homologous recombination in embryonic stem cells to generate de novo chromosomal translocations or to mimic the consequence of these translocations. In addition, chromosomal translocation genes and their products are important targets for therapy. We have designed new therapeutic strategies which include antigen-speci®c recruitment of endogenous cellular pathways to aect cellular viability and a novel structured form of antisense to ablate the function of fusion mRNAs. We will evaluate these procedures in the mouse models of chromosomal translocations and the long term aim is to perfect rapid procedures for characterizing patient-speci®c chromosomal translocations to tailor therapy to individual patients. Oncogene (2001) 20, 5763 ± 5777.
Introduction

Cloning genes at chromosomal translocation breakpoints
The molecular cloning of chromosomal translocation junctions and of cDNA copies of genes aected by the chromosomal translocations resulted in a plethora of dierent translocations being studied (reviewed in . For lymphoid tumours, one of the ®rst clues came from the mapping of the human immunoglobulin (Ig) heavy chain locus to the long arm of chromosome 14 (Croce et al., 1979; Hobart et al., 1981) . At the time, gene mapping by chromosome in situ hybridization was restricted to multi-copy genes but we used the technique to map the human K light chain genes to chromosome 2, band p12 (Malcolm et al., 1982) , using a variable region probe (which is eectively multi-copy due to cross hybridization between dierent V genes (Bentley and ). The presence of antibody genes on 14q and 2p coincided with positions of chromosomal translocation breakpoints in the Burkitt's lymphoma B cell tumour (Bernheim et al., 1981; Klein, 1981) suggesting that rearrangement of Ig genes might be associated with these aberrant chromosomes (Rabbitts, 1983) . The demonstration that rearrangement of genomic fragments of the CMYC oncogene coincide with Ig gene rearrangement clinched this proposal (Dalla-Favera et al., 1982; Taub et al., 1982) and subsequent cloning of translocated CMYC revealed many features of the mechanism and consequences of chromosomal translocations (reviewed in . The association of the rearranging antigen receptor genes with chromosomal translocations in leukaemia was taken further when the T cell receptor (TCR) b chain locus was mapped to chromosome 7, band q35 (Rabbitts et al., 1985) , suggesting that chromosomal translocations in T cell tumours are mediated by the intrinsic chromosomal instability of TCR genes, which undergo rearrangement in normal lymphoid lineage development. This was con®rmed by cloning of LMO1 and LMO2 at chromosomal translocation junctions with TCRd and TCRa (Boehm et al., 1988a McGuire et al., 1989; Royer-Pokora et al., 1991) and of HOX11 and LMO2 at chromosomal translocations with TCRb Dube et al., 1991; Hatano et al., 1991; Kennedy et al., 1991; Lu et al., 1991) .
Lymphoid chromosomal translocations are linked to mechanisms of antigen receptor diversity
In the lymphoid tumours, the breakpoints of chromosomal translocations occur within the Ig or TCR genes, exactly at the junctions of diversity (D) or joining (J) segments, which is where the RAG-recombinase joins V genes during intra-chromosomal antigen receptor gene joining. Thus the VDJ recombinase enzyme is most likely involved in creating these lymphoid-speci®c chromosomal translocations. The sequence speci®city on the reciprocal chromosome is less clear, although certainly some junctions do carry the hallmark of recombinase recognition signals and in those cases recombinase must be involved on both chromosomes. Further, in Burkitt's lymphoma the translocated CMYC gene shows somatic mutations (Rabbitts et al., 1983 (Rabbitts et al., , 1984 in a manner analogous to mutations of V genes further suggesting that lymphoid chromosomal translocations involve natural genetic instability of Ig genes. Indeed some Burkitt's lymphoma cell lines have been identi®ed in which the process of somatic V gene or CMYC mutation can still be observed (Bemark and Neuberger, 2000; Sale and Neuberger, 1998) . We conclude that chromosomal translocations into Ig/ TCR genes occur by mistakes of mechanisms evolved for diversi®cation of the immune system.
Chromosomal translocations and sarcomas
Are chromosomal translocations involving speci®c oncogenes restricted to tumours of haematopoietic origin? Whilst epithelial tumours (which comprise 495% of human tumours) have few recorded recurring, balanced chromosomal translocations (see http://cgap.nci.nih.gov/Chromosomes/Mitelman), sarcomas (mesenchymal tumours) have well characterized abnormalities (see . We set out to clone an example of this group, namely the chromosomal translocation t(12;16)(q13;p11) from malignant myxoid liposarcoma and found that the chromosomal translocation-junctions occurs in a gene on chromosome 16 which we called FUS (Rabbitts et al., 1993) (also called TLS; Crozat et al., 1993) and the CHOP gene on chromosome 12. This resulted in a fusion gene, analogous to the BCR ± ABL gene which had ®rst been described in chronic myelogenous leukaemia (de Klein et al., 1982) , encoding an FUS ± CHOP protein. This observation con®rmed that chromosomal translocations in mesenchymal tumours cause fusion proteins and functional studies of the FUS ± CHOP protein suggested that a DNA-binding transcriptional activator had been created out of a repressor (Sanchez-Garcia and Rabbitts, 1994) , adding verisimilitude to the notion that transcription factors are a major target of chromosomal translocations.
Questions
The consistent occurrence of chromosomal translocations in human tumours has been established from many studies. Several important questions were raised by this earlier work:
. Can any general principles be enumerated about the type of gene activated by chromosomal translocations? . Why are speci®c chromosomal translocations found in speci®c cell types (tumour tropism)? . Can mouse models of chromosomal translocations be developed? . Since chromosomal translocations are somatically created, and thus are tumour-speci®c within an individual patient, can they or their products be used as therapeutic targets?
These questions will be analysed in this article.
Chromosomal translocation master gene model: 10 years
Early analysis of gene structure after chromosomal translocations had occurred showed that either gene fusion or oncogene activation (enforced expression due to the new chromosomal environment) had resulted (reviewed in . Further, it became clear in the early 1990s that transcription factors were a frequent target of chromosomal translocations (Cleary, 1991; Rabbitts, 1991) but that a clear distinction could be drawn between chromosomal translocations in chronic and acute leukaemias (Rabbitts, 1991) and only the latter category involved transcription factors. This led to the chromosomal translocation-master gene model (Rabbitts, 1991) , which postulated that transcription regulators and developmental regulators were the major target of chromosomal translocations, and that their enforced expression or gene fusion, altered the balance of transcription thereby aecting the control of cell fate in the aicted cell. The chromosomal translocationgenes in acute cancers are upstream master genes whose products control downstream pathways. Therefore, a major part of the tropism of chromosomal translocations is due to the speci®city of transcription factor interactions which occur after the chromosomal translocation and the consequent eect on transcription pathways. The essential role of chromosomal translocation genes in acute cancer is in cell fate decisions, perhaps oering an explanation for the scarcity of speci®c chromosomal translocations in epithelial tumours, which may not be in¯uenced by master regulators in this fashion.
The LMO2 gene and its protein
The LMO2 gene in T cell acute leukaemias (T-ALL) is a paradigm of a chromosomal translocation-master gene (reviewed in Rabbitts, 1998) . LMO2 belongs to a family of four genes encoding small LIM-only proteins, two of which are involved in independent chromosomal translocations causing T-ALL (Table 1) . LMO2 is located on chromosome 11, band p13 and is activated by chromosomal translocations with 14q11 or 7q35 (Figure 1a ), speci®cally in T cells. which is a consistent feature of the chromosomal translocation-master gene products. LMO2 can bind to TAL1/SCL (another T-ALL translocation associated protein), LDB1 and GATA-1 in a DNA-binding complex found in erythroid cells (Wadman et al., 1997) . This complex can bind to a bipartite DNA site, comprising an E box separated from a GATA site by about 12 base pairs (Figure 1c) . By studying T cell tumours arising in an Lmo2-gain-offunction transgenic mouse model, we have been able to detect an analogous Lmo2-associated complex, in this case which binds a bipartite sequence comprising tandem E boxes. The putative complex binding to this site is shown in Figure 1c . These observations lead to two conclusions. Firstly, as Lmo2 appears to be a bridging component of the protein complex detected in erythroid cells, it seems possible that the components of the Lmo2-complex might vary through-out haematopoietic dierentiation, controlling various, stagespeci®c functions by regulating sets of genes. A The LMO gene family (LiM-Only genes and previously called RBTN and TTG genes) has four known members. LMO1 (previously RBTN1/TTG1) was identi®ed ®rst and then LMO2 (previously RBTN2/TTG2) and LMO3 (previously RBTN3 (Rabbitts, 1998) and LMO4. LMO1 and LMO2 are both located on the short arm of chromosome 11 and are both involved in independent chromosomal translocations in human T cell acute leukaemia. LMO2 is the most commonly involved in chromosomal translocations and can be activated by association with TCRg, TCRa (14q11) or TCRb (7q35). As yet, LMO3 or LMO4 have not been found in association with any chromosomal translocations Figure 1 LMO2-associated chromosomal translocations, gene and protein. The LMO2 gene was discovered by cloning the breakpoints of chromosomal translocations t(11;14)(p13;q11) and t(7;11)(q35;p13) (Rabbitts, 1998) . (a) The breakpoints of the chromosomal translocations t(11;14)(p13;q11) occur within the TCRd and TCRa genes on chromosome 14 and upstream (5') of LMO2 on chromosome 11. In the variant chromosomal translocation t(7;11), the chromosome 7 break occurs within the TCRb gene. All known breakpoints occur upstream of one of the two promoters (Royer-Pokora et al., 1995) controlling the LMO2 gene. The three exon gene codes for a protein of 156 amino-acids. (b) The LMO2 protein comprises two LIM domains with small upstream and downstream segments (Boehm et al., 1990 . Each LIM domain has two LIM ®ngers, each with a zinc atom coordinated between cys and his residues. The characteristic feature of the LIM domain is two amino acids separating the LIM ®ngers. (c) The role of the LIM domain is in protein-protein interaction. LMO2 binds to TAL1/SCL (a helix ± loop ± helix protein, which in turn binds to the helix ± loop ± helix protein E47), to LDB1 and to GATA-1 in a multi-protein complex able to bind a bipartite DNA sequence comprising an E box (CANNTG), and a GATA site, (Wadman et al., 1997) in erythroid cells. The LMO2 and LDB1 molecules appear to bind as bridging components, although the exact nature and stoichiometry of this complex has not be elucidated. The ability of the LMO2-containing complex to bind DNA indicates a role in control (positive or negative) of target gene expression. If other complexes, involving Lmo2 occur at other stages of haematopoiesis, these might bind and control distinct sets of target genes. An analogous complex was found in T cell tumours arising in CD2-Lmo2 transgenic mice (Grutz et al., 1998) .
The complex binds to a bipartite DNA site but dierent from the one found in erythroid cells (in this case, two adjacent E boxes) and composed of dierent proteins. The T cell tumour complex appears to be involved in control of gene expression, which has a primary eect on T cell dierentiation (see Figure 4) corollary is that Lmo2 has distinct roles in control of haematopoietic cell fate. Secondly, the role of LMO2 in T-ALL is probably by enforced formation of protein complexes (the direct result of enforced LMO2 expression after the chromosomal translocation). Thus gene regulation via LMO2-complexes may be aected; this may occur by direct DNA-binding complexes or by sequestration of proteins from their normal roles (Rabbitts, 1998) .
The LMO2 master gene: a regulator of cell fate in haematopoiesis and vascular formation
The role of Lmo2 in controlling cell fate in normal haematopoiesis has been documented mainly by gene targeting experiments (summarized in Figure 2 ). The generation of null mutation of the Lmo2 gene demonstrated that the gene is necessary for primitive erythropoiesis in mouse embryogenesis ( Figure 2a ) and for de®nitive haematopoiesis (Yamada et al., 1998) . The latter may be at the level of the pluripotent stem cell, at the level of the immediate multi-potential progeny or even perhaps before this, when mesoderm gives rise to these precursors ( Figure  2a ). Furthermore, Lmo2 has a speci®c intraembryonic expression pattern, in endothelial cells and blood progenitor cells (Figure 3 ) (Delassus et al., 1999; Yamada et al., 2000) . In mouse embryogenesis, haemangioblasts (putative common precursors of endothelium and blood cells) are thought to arise from unspeci®ed posterior mesoderm and thus the primary capillary network is made from these haemangioblasts. The ®rst process of vasculature construction, in which the capillary network is formed, is called vasculogenesis. The more mature vascular system is made by the remodelling of primary capillary network, in the process called angiogenesis (Hanahan and Folkman, 1996) . Again use of null mutations of the Lmo2 gene (Yamada et al., 2000) , showed that formation of the primary capillary network does not require Lmo2 but re-modelling into mature vessels does. Thus Lmo2 is necessary for angiogenesis, but not for vasculogenesis. In summary, Lmo2 is expressed in both endothelial cells and blood progenitor cells, and has dual functions in controlling cell fate in haematopoiesis and angiogenesis. These processes seem to be regulated via the ability of the Lmo2 protein to participate in multiprotein complexes aecting gene expression.
The LMO2 master gene: a regulator of cell fate in T cell leukaemogenesis LMO2 is a master gene in the haematopoietic lineage. A role in cell fate decisions accounts for the function of LMO2 in T-ALL development after chromosomal translocation (Rabbitts, 1998; Rabbitts et al., 1999) . A gain-of-function transgenic mouse model of T cell expression of Lmo2 speci®cally in T cells has been informative. Two features of this mouse model are important (Figure 4 ). Lmo2 gene expression was enforced in the T cell lineage using a T cell speci®c promoter, CD2 (Fisch et al., 1992) (Figure 4a ). This resulted in transgenic mice which develop clonal T cell tumours with a long latency (average 9 months) but in large proportion of mice ( Figure 4b ) (Larson et al., 1994 (Larson et al., , 1995 . The long latency implies that the transgene is necessary but not sucient for overt tumour development and that mutations in other genes must occur to compliment the eect of the transgene. The nature of these secondary mutations is obscure at present but one source of the changes has been ruled out, viz. RAG recombinase-mediated mutations. It has been shown that RAG can cause transposition as well as intra-chromosomal rearrangements (Agrawal et al., 1998; Hiom et al., 1998) raising the possibility that it could also make mutations. If so, these mutations do not appear to be the ones needed in the transgenic mouse model because the rate and incidence of tumours in the transgenic mice is identical in the presence or absence of the RAG1 gene ( Figure 4b ).
An important feature of the latency period in the Lmo2-transgenic mouse model is that we observed the accumulation of CD47, CD87 double negative (DN cells) T cell precursors in the thymus of these mice (Larson et al., 1994 (Larson et al., , 1995 . These DN cells are the precursors of the mature double positive (DP cells) T cells and their developmental is inhibited in the thymus by enforced expression of Lmo2. The overt T cell tumours appear to arise from this population of DN cells since we observe comparable T cell tumour formation in RAG17/7; CD2-lmo2 (RAG7/7 mice have a complete block at the DN stage; (Fischer and Malissen, 1998) and RAG+/7 CD2-lmo2 transgenic mice (Drynan et al., 2001) .
These data suggest a model in which enforced expression of Lmo2 has an eect on T cell development within the thymus ( Figure 4c ) without a signi®cant eect on thymus cellularity and these DN T cell precursors are the subject of mutations, which eventually accumulate in clones to result in the clonal T cell tumours appearing. This mouse model is highly relevant to the mechanism of T-ALL occurrence by LMO2 enforced expression following chromosomal translocation. The site of the chromosomal translocation breakpoints occur within TCR genes and speci®c VDJ recombinase recognition-like sequences are found at the breakpoints near the LMO2 gene (Boehm et al., 1988b; Sanchez-Garcia et al., 1991) suggesting that RAG recombinase mediates the chromosomal translocations. Furthermore, recombinase is expressed in the human T cell DN precursors analogous to those which we observed to accumulate as a result of Lmo2-gainof-function in our transgenic mice (Larson et al., 1995) . It seems very likely that this is the population of T cells in which the recombinase-mediated chromosomal translocations occur in humans ( Figure 4c ). The chromosomal translocation provides the cells for overt disease to occur following further mutations in other oncogenes or suppressor genes. It is a corollary that in humans, chromosomal translocations of this type may not always result in overt cancer, as other mutations may not always occur.
Mouse models of chromosomal translocations
A key issue about the role of chromosomal translocation-genes is their tumour tropism i.e. why are speci®c chromosomal translocations mainly found in one cell type, e.g. t(11;14)(p13;q11) in T-ALL, t(9;11)(q21;q23) in acute myeloid leukaemia or t(12;16)(q13;p11) in myxoid liposarcoma? The reason may simply be mechanistic in that speci®c chromosomal translocations may only take place in certain cell types where accessibility allows for inter-chromosomal events between genes with`open' chromatin. Alternatively, the translocation-gene product may exert a critical eect on a speci®c cell type by altering cell physiology. Given that`master-gene' targets of chromosomal translocations are transcription and development regulators, the latter seems most likely. Mouse models of tumour formation are valuable for investigating this problem but also in obtaining information about initial stages of disease which might ultimately be valuable for early detection or treatment. Ideally, the model should emulate as closely as possible the eects of the equivalent human chromosomal translocation, both in timing and cell speci®city of the translocation and its biological outcome. The gain-of-function Lmo2-mediated model discussed above was informative as the outcome was dictated by tissue speci®c expression (i.e. expression only in T cells). Such speci®city is not always easily achieved. Accordingly, we have evaluated the use of homologous recombination to create the equivalent of chromosomal translocation-genes in ES cells followed by generation of mice carrying these targeted genes.
An Mll-Af9gene fusion knock-in tumorigenesis model
The ®rst generation constructs were designed to introduce cDNA sequences into a target gene by homologous recombination (the gene fusion knock-in approach; Corral et al., 1996) and we chose to introduce AF9 sequences in the Mll gene (Figure 5a ). The choice of MLL fusion genes as a test system for the knock-in technology was based on two main features of MLL-associated chromosomal translocations in humans. Firstly, MLL is involved in a large spectrum of dierent fusions in all types of haemato- Figure 2 Lmo2 is necessary for adult haematopoiesis and angiogenesis in mice. The LMO2 gene is a master regulator of cell fate in haematopoiesis as shown by mutational analysis in mice. (a) Lmo2 null mutations introduced into the germ-line of mice cause lethality at E9-10 due to a failure of yolk sac erythropoiesis . In addition, the contribution of embryonic stem cells with homozygous null mutation of Lmo2 to haematopoietic cell populations showed that de®nitive haematopoiesis in adult mice is dependent on Lmo2 (Yamada et al., 1998) . Thus the Lmo2 gene product is required for both embryonic and adult haematopoiesis in mice. (b) The formation of haematopoietic cells and vascular endothelium is thought to occur through a putative precursor cell, the haemangioblast, which derives from the posterior mesoderm. Formation of the capillary network de novo (vasculogenesis) precedes a remodelling of the existing endothelium (angiogenesis). Studies with the Lmo2-lacZ null ES cell derivatives in chimaeric mice showed that the Lmo2 gene is necessary only for the latter process of angiogenesis (Yamada et al., 2000) . The failure of adult haematopoiesis may be due to the failure of angiogenesis in null Lmo2-cells as haematopoietic cells may arise in large blood vessels which do not form in the absence of Lmo2. An alternative origin for haematopoietic cells is directly from haemangioblasts poietic cells and a model system for this gene would help assess the various fusion genes thus obtained. Secondly, the most common MLL-associated chromosomal translocations involving AF9 and AF4 genes appear in myeloid and lymphoid tumours respectively, thereby predicting clearly distinct tumour phenotypes in mouse models. Accordingly, in our ®rst approach, we knocked-in AF9 into one allele of Mll in ES cells and made mice heterozygous for the Mll-Af9 fusion gene (Figure 5b ) (Corral et al., 1996) . This is an imperfect system because the fusion gene is present in the germ-line of the mice and thus does not give the speci®c haematopoietic expression found for the naturally occurring MLL-AF9 fusion after chromosomal translocation. Although this did not seem to be a problem for Mll-Af9, we were unable to use the same approach with an Mll-Af4 fusion suggesting that there may be a cell non-autonomous eect of Mll-Af4 in embryogenesis.
Mll-Af9 knock-in mice developed myeloid leukaemias ( Figure 5c ) with a latency of about 6 months (Corral et al., 1996; Dobson et al., 1999) . The features of the disease found in mice paralleled those in humans where the t(9;11) chromosomal translocation predominates in myeloid rather than in lymphoid leukaemia (Dobson et al., 1999) . This outcome indicates that the Mll-Af9 fusion gene created by the knock-in approach was mimicing the relevant, key features of the pathological eects of the t(9;11) translocation. At face value, these data argue that the the Mll-Af9 fusion gene, which is present in all haematopoietic cells, including the stem cells, has a specifying role in the cellular phenotype of the leukaemia, in turn implying that the Mll-Af4 fusion gene would specify lymphoid leukaemia. However, we cannot exclude a default pathway which leads to myeloid leukaemia when damage is done to the Mll gene. Indeed some support for this proposal was obtained when we observed myeloid leukaemias arising in mice with a knock-in of the lacZ gene into Mll (Dobson et al., 2000) , suggesting loss of the 3' part of Mll or release of the 5' part from the 3' part may be crucial. In developing a ®nal model, we must have results with the Mll-Af4 fusion as this is invariably found in lymphoblastic leukaemias in humans and it is a crucial test for these mouse models.
De novo chromosomal translocations in mice using cre-loxP recombination An alternative approach to mimicing chromosomal translocations is the use of the Cre-loxP recombination system in ES cells to induce de novo chromosomal translocations (Smith et al., 1995; van Deursen et al., 1995) . This has the advantage that tissue speci®c expression of the Cre recombinase would allow the translocation to occur in a tissue speci®c manner and, in addition, the de novo chromosomal translocation Figure 3 Lmo2 expression in vascularization of mouse embryos. A targeted ES clone with one null Lmo2 allele, in which the lacZ gene was knocked-in as a gene fusion with Lmo2, was injected into blastocysts and germ-line transmission of the Lmo2 null allele was obtained (Yamada et al., 2000) . Heterozygous mice were crossed with C57/B16 mice and embryos obtained at E10.5 and E12.5. These embryos were stained with Xgal as a substrate for b-galactosidase activity. Blue staining denotes areas of b-galactosidase due to Lmo2-lacZ gene expression. (a) E10.5 embryo. X-gal staining was seen on major blood vessel walls and capillaries of whole body. would yield both reciprocal chromosomes. We have initiated studies in this area and have described preliminary results with a mouse model in which de novo chromosomal translocations are made between the endogenous Mll and Af9 genes (Collins et al., 2000) . Our strategy for making the Mll-Af9 translocator mice is summarized in Figure 6 . Homologous recombination was used to introduce loxP recombination sites, which are the substrates for Cre recombinase, into Mll (mouse chromosome 9) and Af9 (mouse chromosome 4) genes. These mice were crossed with a transgenic line expressing Cre recombinase to facilitate development of inter-chromosomal translocations. The reciprocal translocation junctions were detectable in mice carrying Mll-loxP and Af9-loxP and expressing Cre recombinase. We conclude that Cre-dependent, loxP mediated inter-chromosomal recombination has occurred in the translocator mice creating the derivative der4 and der9 chromosomes during their development ( Figure 6 ).
Our initial objective was to determine if it were possible to obtain and detect inter-chromosomal translocation in mice using Cre recombinase expressed from a transgene. The ®rst demonstration of this using Mll and Af9 genes (Collins et al., 2000) ; means that the relevant chromosomes in mice behave like their human counter-parts and that the organization of Mll and Af9 genes on their respective chromosomes is appropriate for production of the Mll-Af9 fusion mRNA. In order to see eects on tumour development and tropism of chromosomal translocations, however, it will be necessary to express the Cre recombinase in a tissue and cell-speci®c manner during haematopoiesis, to harness the ability of chromosomal translocations to occur in dierent cell types. In this way, we hope to determine whether tumours arise in a tissue-speci®c manner and we are currently assessing its eects on cellular dierentiation and tumorigenesis. Finally, other Cre-loxP mediated strategies are also under evaluation in an attempt to ®nd a generic approach to mimicry of tumour-associated chromosomal translocations in mice.
Experimental therapeutics applied to chromosomal translocation products
The presence of chromosomal translocations in human tumours is both a diagnostic and prognostic feature. In addition, these well characterized mutations occur Figure 4 Tumorigenesis in an Lmo2 gain-of-function transgenic mouse model of T-ALL. (a) A gain-of-function transgenic mouse model creating enforced Lmo2-expression in T cells using the CD2-promoter/enhancer has been described (Fisch et al., 1992; Larson et al., 1994) . These mice have thymus expression of Lmo2. (b) Mice carrying the CD2-lmo2 transgene develop clonal T cell tumours with a long latency indicating that mutations in other genes are required before the development of overt disease and therefore that the transgene is necessary but not sucient for tumour formation in this model. During the pre-symptomatic period, transgenic mice displayed an accumulation of immature CD47, CD87 double negative (DN) T cells precursors in the thymus (Larson et al., 1995 . This population of T cells expresses RAG VDJ recombinase genes but these are not responsible for the secondary mutations as CD2-lmo2 mice develop tumours at the same rate whether or not these are null for the RAG1 gene (Drynan, Hamilton and THR, submitted). (c) As the DN T cells are the target cells in the transgenic mouse model and as the chromosomal translocations in humans are mediated by VDJ recombianse, the DN cells are likely to be the target cells in which the chromosomal translocations are eective in aetiology of the human disease, and from which the overt leukaemias arise somatically and thus the translocated chromosomes, the aected genes, their transcripts or translation product are possible targets for therapy. Although, highly speci®c to tumour cells, straightforward antibody therapy is not an option since chromosomal translocation-genes and their products are intracellular. This is a problem for design of therapies. We have begun to develop experimental therapeutic strategies for these intracellular targets, with speci®city of interaction as the main goal. We have described two approaches, one using the recruitment of an endogenous cellular pathway (i.e. the apoptosis pathway) via recognition of a chromosomal translocation-antigen (Tse and Rabbitts, 2000) and another using a novel structured or masked antisense RNA approach (Stocks and Rabbitts, 2000) .
Selection of intracellular antibodies for binding chromosomal translocations products
Chromosomal translocations often result in tumourspeci®c fusion proteins (tumour antigens) which are intracellular targets. While antibodies have evolved to bind to antigen with high speci®city, they usually function outside cells and further the presence of disulphide bonds can be deleterious for intracellular Folding. As an approach to overcome these problems, we have developed a method to isolate antibodies, in the form of single chain Fv fragments (scFv), which are functional in vivo as intracellular antibodies (ICAbs) and can be expressed, or otherwise introduced into cells, to bind their target antigen. As scFv are not well suited to intracellular folding and stability, we initially found that very few scFv bind to antigen in vivo. This de®ciency indicated the need for an in vivo screening approach and an antibody-antigen interaction screen was developed (Intracellular Antibody Capture Technology, IACT) which allows direct selection of intracellular antibodies (scFv) (Tse et al., 2001; Visintin et al., 1999) . The technology uses a three-step approach (Figure 7 ). First soluble antigen is displayed on a surface and a phage antibody library (Winter et al., 1994) is panned on the antigen. All phage binding to the surface are recovered (Figure 7a ), the DNA isolated and the scFv cloned in a yeast expression vector as a fusion with the VP16 activation domain. This yeast`sub-library' comprises antigen-speci®c ICAbs together with contaminating ICAbs which derive from the non-speci®c background. The yeast scFv-VP16 fusion clones are screened with an antigen Figure 5 Fusion of Mll and AF9 genes by homologous recombination knock-in. The MLL gene is involved with more than 30 distinct chromosomal translocations in human leukaemias. In order to assess the potential role of the fusion proteins in the tropism of these leukaemias, we established an homologous recombination knock-in strategy for creating the Mll-Af9 gene fusion in mice (Corral et al., 1996) . (a) A targeting vector of humanAF9 cDNA sequences fused to exon 8 of mouse Mll was made to facilitate recombination with the Mll gene in ES cells. Homologous recombination would create a fusion of AF9 in one Mll allele, allowing transcription of an Mll-AF9 fusion mRNA and in turn production of Mll-AF9 fusion protein. (b) Targeted ES cells were identi®ed and injected into blastocysts for production of chimaeric mice and breeding to produce heterozygous carriers of the Mll-AF9 fusion gene. (c) Leukaemias arise in both chimaeric and heterozygous Mll-AF9 knock-in mice. The latency was around 6 months and most mice succumb by 14 months. The majority of tumours were Mac-1+, Gr-1+ myeloid tumours (Dobson et al., 1999) , similar in phenotype to the majority of tumours found human leukaemias with t(9;11) bait expressed in yeast as a fusion with the Lex A DNA-binding domain to separate speci®c ICAbs from non-speci®c ones (Figure 7b) (Visintin et al., 1999) . Finally the selected scFv are veri®ed for binding to antigen in a mammalian cell assay. Thus while most randomly selected scFv do not bind antigen in vivo with sucient anity to be useful, those isolated by the IACT can be used as intracellular reagents.
Effector functions on ICAbs: recruitment of cellular pathways for therapy and the Aida strategy An ideal method of cancer treatment would be to selectively destroy tumour cells whilst sparing the normal counterparts. One approach is to recruit endogenous cellular pathways to elicit a response on a target cell, mediated through a target antigen speci®cally in that cell (e.g. a chromosomal translocation fusion protein). There are several endogenous pathways which could be invoked including apoptosis, proteolysis, signal transduction and transcription pathways (Figure 8a) . We have developed a recruitment strategy using binding of ICAbs to target antigens to activate an endogenous pathway which relies only on the presence of antigen in the cell and not on its function per se. In our ®rst approach, a technique for speci®c cell killing was developed (the Antibodyantigen Interaction Dependent Apoptosis, Aida, method) in which tumour cells are induced to commit suicide following binding of ICAb scFv to an intracellular antigen. In a model system, we have demonstrated that scFv fused to caspase 3 can cause auto-activation of the caspase 3 after binding to antigen, subsequently causing cell suicide (Tse and Rabbitts, 2000) . The rationale is that caspase 3 (the socalled executioner of the programmed cell death or apoptosis pathway) exists as an inactive pro-caspase and on dimerisation can be induced to auto-cleavage (MacCorkle et al., 1998) and activation of downstream caspases of the endogenous programmed cell death or apoptosis pathway (Figure 8b) . Therefore, if dimerisation of exogenous caspase 3 could be induced by antigen, we can recruit endogenous downstream caspases and kill the cell. We have achieved this in our Aida method by expressing in tumour cells ICAb as scFv fused to pro-caspase 3 (Figure 8c ). Binding to antigen inside cells with appropriate localisation of two independent scFv-caspase 3 molecules induces apoptosis (Figure 8d) .
Our model Aida experiment employed b-galactosidase as antigen which is known to be a natural tetramer (Jacobson et al., 1994) and an anti-b gal ICAb scFv (scFv-R4; Martineau et al., 1998) which binds to antigen in vivo but does not neutralize its activity. The rationale was that two or more scFv-caspase 3 molecules should bind per antigen tetramer and initiate apoptosis through the regional association and activation of the caspase molecules (Tse and Rabbitts, 2000) . Apoptosis was detected in CHO cells transfected with antigen and R4-scFv-caspase 3 as determined by appearance of both the caspase 3 cleavage product and of the chromosomal DNA cleavage ladder typical of cells undergoing apoptosis (Tse and Rabbitts, 2000) . This eect is antigen-dependent, antibody-speci®c and required active caspase 3 fused to the ICAb (Figure 9 ). Thus cell suicide or apoptosis is caused if antibody, in the form of scFv physically linked to caspase 3, binds to antigen in vivo in two or more close positions.
This method adds eector functions to the ICAbs and has several important potential uses in cancer therapy targeting chromosomal translocation gene products. If two antibodies could be isolated which can bind to sites on a fusion protein (Figure 8d ), on either side of the fusion junction, then tumour speci®c cell killing should result. Furthermore, cells expressing oncogenic proteins with mutations could be targeted if a mutant-speci®c scFv could be expressed or introduced in the tumour cells along with a second scFvcaspase molecule binding to a site close enough to the anti-mutant scFv-caspase to allow auto-activation of the caspase. In those mutant proteins which form natural tetramers, such as p53, it may only be necessary to introduce one scFv-caspase as the apoptosis induction should occur in a manner analogous to that described for b-galactosidase. The Figure 6 The Mll-Af9 translocator mouse. Mouse Mll and Af9 genes are located on chromosomes 9 and 4 respectively (Collins et al., 2000; Ma et al., 1993) . The mice which carry both Mll and Af9 chromosomes with loxP sites introduced by homologous recombination can be induced to undergo inter-chromosomal recombination by expressing Cre recombinase, to generate the derivative 9 and derivative 4 chromosomes. This translocator mouse line can be maintained with the genotype (Mll-loxP/loxP; Af9 loxP/loxP) and therefore tissue-speci®c chromosomal translocations are inducible by inter-breeding with mice expressing Cre in a speci®ed way. For instance, we have found T cell-speci®c inter-chromosomal recombination of Mll and Af9 in mice expressing Cre under the control of the Lck T cell promoter (unpublished data) latter might also apply to situations like AML ± ETO/ MTG8 and PML ± RAR which oligomerize in tumour cells (Minucci et al., 2000) .
Masked antisense
Fusion genes made by chromosomal translocations are transcribed into the corresponding mRNA and the junction between sequences, originating from the exons of the fused genes, represents a unique sequence, only found in the mRNA of cells carrying the chromosomal translocation. Short anti-sense oligonucleotides have been designed to target this sequence and cause mRNA degradation or prevent protein synthesis from the fusion mRNA. The use of short oligonucleotides in vivo has some problems. They have a limited longevity and form rather unstable hybrids in contact with the target mRNA but, in particular, the hybridization speci®city of short oligonucleotides is a potential problem (Wagner and Flanagan, 1997) . We have developed a procedure which both retains the speci®city of the short oligonucleotide binding to the fusion mRNA junction and incorporates a ®nal stable hybrid between oligonucleotide and fusion mRNA (Stocks and Rabbitts, 2000) .
The procedure uses a masked antisense molecule designed to target the BCR ± ABL fusion mRNA as a model. The structure of this antisense molecule is shown in Figure 10a . There are two hair-pin structures (designated stem/loops I and II) between which is a short sequence of eight nucleotides (the nucleation targeting region) which serves to speci®cally hybridize to the ABL side of the BCR ± ABL mRNA junction. Stem/loop II comprises BCR antisense sequences masked in the form of a stable stem loop. This stretch of antisense can only begin to hybridize to the BCR mRNA immediately adjacent to the BCR ± ABL junction when the masked antisense hybridizes to target BCR ± ABL mRNA via the nucleation site. There is then progressive hybridization of antisense and sense by the thermodynamically favourable process of branch-migration. As this proceeds, a longer and longer hybrid is formed until a fully stable duplex is created. The masked antisense cannot hybridize to normal BCR mRNA as the BCR antisense is stably masked in stem/loop II and also cannot stably hybridize to normal ABL mRNA.
A masked antisense molecule was assessed for its ability to bind to various target RNAs in vitro (Figure  10b, c) . Our data show that only the cognate target RNA was recognized in such a way that a stable hybrid formed between it and the masked antisense. In addition, preliminary experiments using expressed masked antisense molecules further indicated that these species are expressed, fold adequately and can ®nd their target mRNA for hybrid formation in vivo (Stocks and Rabbitts, 2000) . The ecacy and speci®city of masked antisense makes these novel RNAs uniquely suited to therapy involving targeting to fusion mRNAs emanating from chromosomal translocations. (a) is prepared and the scFv DNA fragments are sub-cloned into the yeast VP16 expression vector (Visintin et al., 1999) to give a yeast scFv-VP16 library. The library is screened in yeast with the antigen`bait' in which antigen (shown in blue) is expressed as a fusion with the LexA DNA-binding domain (shown in orange). Only those scFv that retain the speci®c binding ability in vivo can activate LexA DNA binding site reporters controlling His3 and LacZ genes. These are isolated and tested in mammalian cell lines with appropriate assays for intracellular binding and function
Conclusions
Our work has been aimed at de®ning the types of gene activated by chromosomal translocations and using one example particularly, viz. the LMO2 gene, to illustrate some key features of master regulators controlling cell fate in normal and tumour settings. We have begun to evaluate the potential for the chromosomal translocation gene products as therapeutic targets. In addition, we are developing mouse models of chromosomal translocations to study basic biological cell-speci®c consequences of chromosomal translocations and as experimental therapeutic systems for pre-clinical assessment of therapeutic strategies and reagents.
I would like to highlight four areas where future research and development will be valuable. These are inter-connected and should yield important molecular information about chromosomal translocations to help devise new therapies: . De®nition of the role of chromosomal translocations in tumour cell type. . Studies of chromosomal translocations in epithelial tumours. . Development of new experimental therapeutic technologies for application to cancer treatment using chromosomal translocations and primary or downstream products of genes aected by them.
. Translation of experimental therapeutics into clinical management of cancer.
Definition of the role of chromosomal translocations in tumour cell type
An understanding of the molecular basis of chromosomal translocation tropism is an important goal. Why do particular chromosomal translocations occur in speci®c cell types, and how do these chromosomal translocations work at the molecular level? In acute cancers, chromosomal translocation-genes are upstream master genes encoding transcription factors and enforced expression of oncogenes/fusion oncogenes cause cell fate/developmental abnormalities. Therefore, a major part of the tropism of these chromosomal translocations is due to the speci®city of transcription factor interactions which ensue after the chromosomal translocation and the consequent eect on transcription pathways. The identity of target genes, which are activated or repressed in downstream pathways, is a key issue. The downstream genes will not only be crucial in our understanding of chromosomal translocations in cancer development but will also become part of our repertoire of target molecules for therapeutics. 
Studies of chromosomal translocations in epithelial tumours
The`solid' tumours make up more than 95% of human cancers. We know rather little about the existence of recurrent chromosomal translocations in this group, except for the sarcomas, despite a wealth of cytogenetic information (see http://cgap.nci.nih.gov/Chromosomes/ Mitelman). Some consistent changes are known, such as the translocation t(3;5) in renal cell carcinoma (Kovacs et al., 1987) , but signi®cantly this is an unbalanced translocation, implying a dierent mechanism compared haematopoietic tumours and sarcomas. It may be that dierences in epithelial cell biology, compared with for instance haematopoiesis, account for dierences in the types of chromosomal translocations found and the chromosomal translocation master gene concept may not be applicable to epithelial tumour development. New approaches to the question of chromosomal translocations in epithelial tumours are now possible using multi-colour¯uorescence in situ hybridization (FISH) and analysis of primary tumour material. In addition, the publication of the human genome and cDNA sequences (Nature, 2001; Science, 2001) promises much in the way of expression analysis which may indirectly identify chromosomal translocation gene products. For instance, if fusion genes are a feature of epithelial tumours, cDNA cloning and sequencing should identify these, given that the human genome sequence is now available. However, this may still prove beyond the capacity of current technology as most cDNA library construction techniques are not adequate for the purpose. Most cDNA clones are not full length, many do not even contain coding sequence and most cDNA libraries are representations rather than normalized in any useful way for a mass sequencing approach. Finally, many generally used cDNA cloning methods may generate pseudo-fusion transcripts. Whilst these can easily be sifted by restriction enzyme scanning and by inter-exon RT ± PCR testing of cDNA made from the source mRNA, each fusion identi®ed will need to be evaluated. Despite these caveats, the currently available genome sequence, and its future re®nements and completion, will provide the data for epithelial cancers to be fully described in Figure 9 Aida cell killing of CHO cells expressing target antigen. In model experiments to validate the Aida strategy (Tse and Rabbitts, 2000) , we used an anti-b-galactosidase scFv R4 (Martineau et al., 1998) which binds to b-galactosidase in vivo but does not neutralize its function. In the assay, the level of b-galactosidase activity is monitored as a re¯ection of cell viability (Tse and Rabbitts, 2000) . CHO cells were transfected with plasmids expressing b-galactosidase and the various scFv fusion proteins as indicated on the histogram. b-galactosidase levels were measured 60 h after transfection and the data shown are the representative of two independent experiments, each carried out in duplicate. b-galactosidase levels are expressed relative to those obtained with the pEF-bgal expression vector co-transfected with vector (pEF-BOS) alone (which was taken as 100%). When the anti-bgalactosidase scFv R4 was expressed as a fusion with caspase 3 as an ICAb, cell viability was reduced to around 10% and cell death by apoptosis was con®rmed by detection of the caspase 3 cleavage product and chromatin fragmentation studies (Tse and Rabbitts, 2000) . The scFv-induced apoptosis is antigen speci®c as it only occurred in the presence of b-galactosidase, it is dependent of speci®c antibody binding as non-relevant scFv (F8) (Tavladoraki et al., 1993) fused to caspase 3 showed no eect, and it is dependent on the activity of the fused caspase as an inactivating mutation (C163S) abrogated the eect. Finally, antigen binding alone was insucient to activate apoptosis as scFv R4 fused to a VP16 fragment was ineective terms chromosomal translocations (and of course other mutations). Technology improvement, as is invariably the case, will be crucial to rapidly answer issues about epithelial tumours, to broaden the endeavours into the biological role of chromosomal translocations, as well as the goals of improving cancer treatment and early detection strategies.
While the existence of speci®c chromosomal translocations is uncertain in epithelial tumours, these tumours seem to contain non-recurrent chromosomal translocations which are idiopathic changes (discussed in . Do these changes have any signi®cance for the biology of the individual tumours and are the gene products of any interest as therapeutic targets? If tumour progression, which is associated with genome instability, is accompanied by the accumulation of idiopathic chromosomal translocations these may be biologically relevant to the speci®c tumour but in any event, techniques such as the recruitment of endogenous pathways described above (e.g. Aida cell suicide) which rely on the presence of a protein target, but not its function, will be applicable in this situation.
Developing new therapeutic technologies for cancer treatment
A long term strategy for cancer treatment is tailoredtherapy for individual cancers. This might be possible by exploiting technologies capable of rapid sequencing of chromosomal translocation-gene products and application to rapid methods for production of patient-speci®c therapeutic`drugs'. In the future, it will be possible to pro®le an individual cancer genome shortly after`diagnosis', and in addition diagnosis will Figure 10 Masked antisense molecules to target BCR ± ABL fusion mRNA. The structured or masked antisense format was designed to speci®cally hybridize and inactivate fusion mRNA, either by causing RNA degradation or inhibiting protein synthesis. (a) The sequence and putative secondary structure of a masked antisense speci®c for BCR ± ABL p190 (MAS190a) is shown. Antisense residues are shown in bold. The antisense molecule has two stem-loop structures of which stem-loop two contains 31 bases complementary to BCR. The targeting region (nucleation site) is highlighted in yellow and comprises 8 bases complementary to the ABL sequence at the junction with BCR. The targeted region of BCR-ABL mRNA is shown in orange (indicated 3'?5'). The two forms of the MAS190 molecule, designated a and b, dier only in the descending strand of stem-loop II (the dierences present in MAS190b form are shown in red brackets). Coloured lines indicate the regions complementary to the oligonucleotides used for blocking experiments which con®rmed that the nucleation site was the primary site of hybridization (red=oligo 1, green=oligo 2 and blue=oligo 3). (b) The time course of interaction of either MAS190 a or MAS190 b masked antisense RNA with the p190 BCR-ABL RNA and related sequences. Radio-labelled p190 mRNA fragment (p190(+)RNA) was mixed with MAS190a or MAS190b masked antisense and incubated at 378C. At the indicated times, aliquots were removed and immediately loaded on a continuously electrophoresing 5% native polyacrylamide gel. Samples were run into the gel for 2 min at 10 V/cm then the voltage was reduced to 1 V/cm until the next sample was loaded. After the last sample was loaded (taken at 120 min), electrophoresis was completed at 10 V/cm followed by auto-radiography. The indicated bands correspond to antisense-sense hybrid (AS/(+) RNA), unannealed p190 RNA (p190(+)) and unhybridized antisense (either hAS190a or b). (c) Speci®city of masked antisense interaction with target mRNA molecule. 32 P-labelled masked antisense to BCR ± ABL p190 (MAS190a) or p210 (MAS210) was mixed with the unlabelled target mRNA species indicated at the top of the gel and allowed to associate at 378C for 30 min. The mixtures were resolved by gel electrophoresis, followed by autoradiography. Target mRNA fragments (top) were: BCR ± ABL fusion RNA=p190(+) or p210(+); normal ABL RNA=ABL(+); normal BCR RNA=BCR(+) and an antisense fragment of BCR-ABL p190=p190(7). tRNA indicates reaction carried out with only carrier tRNA be possible at a much earlier stage of disease rather than at the time of presentation with overt cancer. This individual pro®ling will facilitate these tailor-made therapeutics.
Translation of experimental therapeutics into clinical management of cancer
A goal of molecular biology is to describe cancer biology at the molecular level and identify those areas of molecular pathology which are consistent changes. The molecular biology of chromosomal translocations is an example where signi®cant progress has been achieved. We are now in a position to capitalize on this wealth of information for therapy since we can use the molecular information for drug design and develop new strategies to kill or inhibit cancer cells. Protein ± protein interactions are likely to provide many speci®c targets. It is important to keep in mind the continuing need for technological development in this quest, as cancer cells are notoriously good at evading therapy. The strategy we describe here for recruiting endogenous cellular pathways after introducing an exogenous reagent into the cell is one approach. With an increase in the sophistication of techniques for identifying new target molecules and their biological pathways, we need to improve strategic technologies and continue to develop new ones for treatment. Mouse models of chromosomal translocations remain at the forefront of our requirements for a balanced portfolio of methods to translate the molecular biology of chromosomal translocations into pre-clinical experimental therapeutics and ®nally into patient management.
